Short Interest Worth Mentioning: Assembly Biosciences Incorporated (NASDAQ:ASMB) Reports Increase in Sellers; Strong Momentum for Short Players

November 24, 2016 - By Pete Kolinski   ·   0 Comments

Short Interest Worth Mentioning: Assembly Biosciences Incorporated (NASDAQ:ASMB) Reports Increase in Sellers; Strong Momentum for Short Players

The stock of Assembly Biosciences Incorporated (NASDAQ:ASMB) registered an increase of 35.67% in short interest. ASMB’s total short interest was 230,100 shares in November as published by FINRA. Its up 35.67% from 169,600 shares, reported previously. With 45,200 shares average volume, it will take short sellers 5 days to cover their ASMB’s short positions. The short interest to Assembly Biosciences Incorporated’s float is 2.37%. The stock increased 1.18% or $0.15 on November 23, hitting $12.83. About 28,919 shares traded hands. Assembly Biosciences Inc (NASDAQ:ASMB) has risen 118.57% since April 22, 2016 and is uptrending. It has outperformed by 113.16% the S&P500.

Assembly Biosciences, Inc. is a biotechnology company. The company has a market cap of $218.93 million. The Firm is engaged in developing approximately two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus infection, and a class of oral biological therapeutics, which are designed to restore health to a dysbiotic microbiome. It currently has negative earnings. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate a number of Hemoglobin C functions.

ASMB Company Profile

Assembly Biosciences, Inc., incorporated on October 7, 2005, is a biotechnology company. The Firm is engaged in developing approximately two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral biological therapeutics, which are designed to restore health to a dysbiotic microbiome. The Firm has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate a number of Hemoglobin C (HBc) functions. The Company’s Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice (cGMP) conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead program from this platform, AB-M101, is in development for the treatment of C. difficile-infections (CDI). Using its microbiome platform, the Company is developing additional product candidates.

More notable recent Assembly Biosciences Inc (NASDAQ:ASMB) news were published by: Seekingalpha.com which released: “Assembly Biosciences Reaches The Clinic” on November 16, 2016, also Globenewswire.com with their article: “Assembly Biosciences Announces Participation in HBV Scientific Meetings in …” published on September 21, 2016, Globenewswire.com published: “Assembly Biosciences Announces Key Additions to Microbiome Team” on September 28, 2016. More interesting news about Assembly Biosciences Inc (NASDAQ:ASMB) were released by: Quotes.Wsj.com and their article: “News Assembly Biosciences Inc.ASMB” published on March 12, 2011 as well as Globenewswire.com‘s news article titled: “Assembly Biosciences Announces Senior Management Changes” with publication date: February 17, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Pete Kolinski


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>